Antidote

NOVEMBER 30, 2022

Antidote’s podcast, Talk of the Towne , focuses on the ultimate sweet spot: that special place where science and patients converge. Our host, Dr. Rich Towne, was trained in pharmacy and currently works in Clinical Informatics at Antidote. In each episode, Rich welcomes a new guest from an Antidote partner organization, and takes an in-depth look at a particular area of interest, zeroing in on the story that Antidote's data is telling about how best to connect patients and research.

Research 98

Research Pharmacy Science 98

Drug Discovery Today

NOVEMBER 28, 2022

The new facilities will support the increased demand for Optimer technology.

Laboratories 113

Laboratories 113

Drug Patent Watch

DECEMBER 2, 2022

This chart shows the pharmaceutical companies with the most patents in Denmark. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Denmark? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs 52

Cytel

DECEMBER 2, 2022

For 35 years , Cytel’s scientific rigor and operational excellence have enabled biotech and pharmaceutical companies to navigate uncertainty, prove value, and make evidence-based decisions with confidence. To celebrate this milestone, we invited Cytel’s Co-Founders, Nitin Patel and Cyrus Mehta, and CEO, Joshua Schultz, to offer their reflections on Cytel’s beginnings, its innovations in technology and statistical strategy over nearly four decades, and predictions for the future of the industry.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Clinical Trials Clinical Development 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Antidote

NOVEMBER 28, 2022

Osteoporosis and osteoarthritis (OA) are conditions with different causes and symptoms, but because people are often diagnosed with both, the terms are frequently used interchangeably.

98

98

Metabolite Tales Blog

DECEMBER 2, 2022

Hypha’s Q4 2022 newsletter – synthesis of deuterated metabolites In our Q4 2022 newsletter we look at how Hypha make deuterated metabolites, illustrated using case studies where biotransformation and late-stage chemical synthesis techniques were employed. Sign up at the bottom of the page in the link here to receive our quarterly newsletter by email Read newsletter Biotransformation of deuterated flurbiprofen to a deuterated form of the main human metabolite using microbes and recomb

52

52

sptlabtech

DECEMBER 2, 2022

We sat down with Paul Lomax, Head of Genomics at SPT Labtech, to find out how exciting new technological developments have opened up opportunities for widespread innovation. In this interview, Paul touches on the history and current state of play of automation technologies for genomics before giving us a glimpse into what we can look forward to in the near future.

International 52

International Laboratories Research Marketing 52

BMG Labtech

DECEMBER 1, 2022

Proteins are indispensable molecular catalysts of biological reactions and play important structural roles in cells. The way they fold or unfold reveals crucial information about their biological activity.

Science 52

Science 52

The Open Targets Blog

DECEMBER 2, 2022

Artificial Intelligence and Machine Learning (AI/ML) have applications across all areas of drug discovery and development. At Open Targets, our main focus is target identification and prioritisation, and a 2017 analysis by Enrico Ferrero shows that the data linking genes and diseases in the Open Targets Platform is already sufficient to effectively predict novel targets for which therapies are actively being pursued or are already on the market.

Clinical Trials 52

Clinical Trials Trials Drugs Disease 52

Drug Patent Watch

DECEMBER 2, 2022

Annual Drug Patent Expirations for EXPAREL Exparel is a drug marketed by Pacira Pharms Inc and is included in one NDA. It is available from one supplier. There are eight…. The post New patent for Pacira Pharms drug EXPAREL appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Channels

DECEMBER 1, 2022

Today’s guest post comes from Deepak Thomas, Founder and CEO of PHIL Inc. Deepak explains how a manufacturer’s net revenues are affected when that manufacturer helps patients access, afford, and adhere to medication therapy. He provides three suggestions for building a channel strategy to optimize gross-to-net while also improving clinical, financial, and operational outcomes.

Therapies 52

Therapies Drugs 52

The Premier Consulting Blog

NOVEMBER 30, 2022

Computer modeling and simulation of humans, both healthy and with diseases, is a powerful tool. It can augment preclinical and clinical research through mechanistic and predictive investigations that would otherwise be impossible. In recent years, regulatory agencies have begun to accept evidence obtained through modeling and simulation, and in silico clinical trials have emerged as an important approach for virtual testing of pharmacological therapies and medical devices.

Trials 52

Trials Clinical Research Treatment Disease 52

Advarra

DECEMBER 1, 2022

In the past several years, Health and Human Services (HHS) Office of Human Research Protections (OHRP), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) have announced and/or implemented new regulations to address the challenges of conducting clinical trials involving multiple research sites. Chief among these requirements is the use of a designated single institutional review board (sIRB) for multisite research (also known as a central IRB [cIRB]).

Regulations 52

Regulations Compliance FDA Clinical Trials 52

Drug Patent Watch

DECEMBER 2, 2022

Annual Drug Patent Expirations for FOTIVDA Fotivda is a drug marketed by Aveo Pharms and is included in one NDA. It is available from one supplier. There are two patents…. The post New patent for Aveo Pharms drug FOTIVDA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Olympian Clinical Research

DECEMBER 1, 2022

Psoriasis is a chronic, autoimmune skin condition. By speeding up the growth cycle of skin cells, psoriasis creates thick, red patches on the skin that are frequently covered in white scale-like tissue. Various types of psoriasis affect nearly 7.5 million US adults. . The type of psoriasis you experience can influence the symptoms and complications associated with your condition as well as the treatment plan that is right for you.

Clinical Trials 52

Clinical Trials Doctors Clinical Research Treatment 52

Crown Bioscience

NOVEMBER 30, 2022

This post explores applications of genetically engineered organoids and cell lines to expand and accelerate anti-cancer drug discovery and development. We first provide a brief overview of two major methods that are used to develop engineered organoids/cell lines (i.e., lentiviral transduction and PiggyBac), followed by typical workflows for generating these models.

Engineering 52

Engineering Drugs 52

Advarra

DECEMBER 1, 2022

The research informed consent form (ICF) is designed to provide prospective participants with the necessary information to make an informed decision about whether to participate in a clinical trial. Frequently included in the informed consent is an institution’s Health Insurance Portability and Accountability Act (HIPAA) statement, which informs participants of how their protected health information (PHI) may be used or disclosed by covered entities for research purposes.

Clinical Trials 52

Clinical Trials Trials Regulations Research 52

Drug Patent Watch

DECEMBER 2, 2022

Annual Drug Patent Expirations for ASPRUZYO+SPRINKLE Aspruzyo Sprinkle is a drug marketed by Spil and is included in one NDA. It is available from one supplier. There is one patent…. The post New patent for SPIL drug ASPRUZYO SPRINKLE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Cytel

NOVEMBER 29, 2022

Bayesian methods have continuously played a key role in transforming clinical research in therapeutic areas such as oncology and rare diseases, and in addressing clinical development challenges for COVID-19 drugs, devices, and biologics. From early-phase trials to late-phase development, utilizing Bayesian tools can expedite and/or de-risk trials, even when used to augment a Frequentist framework.

Clinical Trials 52

Clinical Trials Trials Clinical Development Clinical Research 52

BMG Labtech

NOVEMBER 29, 2022

What are proteins? Next to carbohydrates, lipids and nucleic acids, proteins are one of the main macromolecule building blocks of life. On a molecular basis, they can be described as complex polymers of amino acids, connected via a peptide bond backbone (fig.1). There are 20 different types of amino acids available as possible residues of individual subunits of a protein.

Science 52

Science 52

Advarra

NOVEMBER 29, 2022

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines. There have been recent signals indicating the Food and Drug Administration (FDA) plans to provide greater support for CGT, addressing key issues continuing to impede their development.

Therapies 52

Therapies Clinical Trials FDA Production 52

Drug Patent Watch

DECEMBER 1, 2022

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Finland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Finland? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals 52

Drug Channels

NOVEMBER 29, 2022

I hope everyone enjoyed the Thanksgiving holiday! Now that you’ve stretched your stomach, stretch your mind with some food for thought. In this issue: Mark Cuban schools Elon Musk on PBMs Market access lessons from Semglee Gen Z rejects the pharmacy career path A potent call for 340B transparency Plus, get ready to love the ‘90s again! P.S. Join my more than 34,000 LinkedIn followers for daily links to neat stuff.

Pharmacy 72

Pharmacy Drugs Marketing Biosimilars 72

Zobio

NOVEMBER 28, 2022

In person On 8th December 2022, the Society for Medicines Research and the Biological and Medicinal Chemistry Sector of the Royal Society of Chemistry were jointly hosting a 1-day meeting in London on Recent Trends in Medicinal Chemistry and Enabling Technologies. The meeting was a combination of medicinal chemistry, chemistry-based drug discovery enabling technologies and.

Research 40

Research Drugs 40

Drug & Device Law

NOVEMBER 26, 2022

Several of your Reed Smith bloggers are making plans to attend ACI’s annual Drug and Medical Device Litigation conference , as they celebrate the 27th anniversary of the event. We’re looking forward to great content and networking opportunities – and the chance to catch up with some of our loyal readers! Since we’d like to see you at ACI, we wanted to share that the good people at ACI asked the blog to be a media sponsor this year – and are offering a special registration discount for the confer

Drugs 59

Drugs 59

Drug Patent Watch

DECEMBER 1, 2022

Annual Drug Patent Expirations for LIVMARLI Livmarli is a drug marketed by Mirum and is included in one NDA. There are three patents protecting this drug. This drug has one…. The post New patent for MIRUM drug LIVMARLI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

DECEMBER 1, 2022

Annual Drug Patent Expirations for MAVYRET Mavyret is a drug marketed by Abbvie Inc and is included in two NDAs. It is available from one supplier. There are nine patents…. The post New patent for Abbvie Inc drug MAVYRET appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

DECEMBER 1, 2022

Annual Drug Patent Expirations for BLUDIGO Bludigo is a drug marketed by Provepharm Sas and is included in one NDA. There is one patent protecting this drug. This drug has…. The post New patent for Provepharm Sas drug BLUDIGO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 30, 2022

This chart shows the drugs with the most patents in Denmark. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Denmark? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Drug Patent Watch

NOVEMBER 30, 2022

[![eltrombopag structure]([link] Eltrombopag is the generic ingredient in two branded drugs marketed by Novartis and is included in two NDAs. There are eight patents protecting this compound. There are four…. The post New tentative approval for Teva Pharms drug eltrombopag appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 30, 2022

[![saxagliptin structure]([link] Saxagliptin is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are two patents protecting this compound. There are…. The post New tentative approval for Amneal Pharms drug saxagliptin appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 29, 2022

This chart shows the drugs with the most patents in Denmark. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Denmark? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Drug Patent Watch

NOVEMBER 29, 2022

Annual Drug Patent Expirations for ELUCIREM Elucirem is a drug marketed by Guerbet and is included in one NDA. It is available from two suppliers. The generic ingredient in ELUCIREM…. The post New patent for Guerbet drug ELUCIREM appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52